Last reviewed · How we verify
Liposomal Amphotericin B with Miltefosine
Liposomal Amphotericin B with Miltefosine is a Antifungal/antiparasitic combination Small molecule drug developed by Banaras Hindu University. It is currently in Phase 3 development for Visceral leishmaniasis, Fungal infections (investigational combination).
Liposomal amphotericin B disrupts fungal cell membranes while miltefosine inhibits phosphatidylcholine synthesis, together providing enhanced antifungal and antiparasitic activity.
Liposomal amphotericin B disrupts fungal cell membranes while miltefosine inhibits phosphatidylcholine synthesis, together providing enhanced antifungal and antiparasitic activity. Used for Visceral leishmaniasis, Fungal infections (investigational combination).
At a glance
| Generic name | Liposomal Amphotericin B with Miltefosine |
|---|---|
| Sponsor | Banaras Hindu University |
| Drug class | Antifungal/antiparasitic combination |
| Target | Fungal ergosterol; phosphatidylcholine synthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Amphotericin B binds to ergosterol in fungal cell membranes, causing leakage and cell death; the liposomal formulation reduces toxicity to human cells. Miltefosine is an alkylphospholipid that inhibits phosphatidylcholine synthesis and disrupts cell membrane integrity in both fungi and parasites. The combination leverages synergistic mechanisms to improve efficacy against resistant organisms.
Approved indications
- Visceral leishmaniasis
- Fungal infections (investigational combination)
Common side effects
- Nephrotoxicity
- Infusion-related reactions
- Hepatotoxicity
- Electrolyte abnormalities
- Gastrointestinal disturbances
Key clinical trials
- Treatment of Mucosal Bolivian Leishmaniasis (PHASE3)
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
- Short Course Regimens for Treatment of PKDL (Sudan) (PHASE2)
- Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (PHASE3)
- Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa (PHASE2)
- Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh (PHASE3)
- Combination Therapy in Indian Visceral Leishmaniasis (PHASE3)
- Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal Amphotericin B with Miltefosine CI brief — competitive landscape report
- Liposomal Amphotericin B with Miltefosine updates RSS · CI watch RSS
- Banaras Hindu University portfolio CI
Frequently asked questions about Liposomal Amphotericin B with Miltefosine
What is Liposomal Amphotericin B with Miltefosine?
How does Liposomal Amphotericin B with Miltefosine work?
What is Liposomal Amphotericin B with Miltefosine used for?
Who makes Liposomal Amphotericin B with Miltefosine?
What drug class is Liposomal Amphotericin B with Miltefosine in?
What development phase is Liposomal Amphotericin B with Miltefosine in?
What are the side effects of Liposomal Amphotericin B with Miltefosine?
What does Liposomal Amphotericin B with Miltefosine target?
Related
- Drug class: All Antifungal/antiparasitic combination drugs
- Target: All drugs targeting Fungal ergosterol; phosphatidylcholine synthesis pathway
- Manufacturer: Banaras Hindu University — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Visceral leishmaniasis
- Indication: Drugs for Fungal infections (investigational combination)
- Compare: Liposomal Amphotericin B with Miltefosine vs similar drugs
- Pricing: Liposomal Amphotericin B with Miltefosine cost, discount & access